Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
21.27
Oct 26 • 3:59 PM ET Dollar change-0.15 Percentage change(-0.70%)
Aftermarket Close
21.27
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
284.59M
Enterprise Value
271.43M
Income
-3.78M
Sales
120.65M
Book/sh
10.26
Cash/sh
2.87
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
235
IPO
May 03, 1993
P/E
-
Forward P/E
22.39
PEG
0.19
P/S
2.36
P/B
2.07
P/C
7.41
P/FCF
508.20
EV/EBITDA
532.22
EV/Sales
2.25
Quick Ratio
3.19
Current Ratio
4.48
Debt/Eq
0.18
LT Debt/Eq
0.17
Option/Short
Yes / Yes
EPS (ttm)
-0.27
EPS next Y
0.95
EPS next Q
0.42
EPS this Y
854.55%
EPS next Y
-9.52%
EPS next 5Y
118.66%
EPS past 3/5Y
9.40% 14.76%
Sales past 3/5Y
-10.28% -2.86%
EPS Y/Y TTM
93.57%
Sales Y/Y TTM
-2.50%
EPS Q/Q
187.26%
Sales Q/Q
15.56%
Insider Own
6.28%
Insider Trans
2.34%
Inst Own
91.77%
Inst Trans
-0.96%
ROA
-1.68%
ROE
-2.19%
ROIC
-2.36%
Gross Margin
62.16%
Oper. Margin
-4.24%
Profit Margin
-3.14%
SMA20
5.76%
SMA50
2.94%
SMA200
34.31%
Trades
Shs Outstand
13.38M
Shs Float
12.54M
52W High
22.88 -7.04%
52W Low
9.01 136.07%
Volatility
3.27% 3.92%
ATR (14)
0.75
RSI (14)
59.55
Beta
0.21
Rel Volume
0.89
Avg Volume
107.99K
Volume
96,164
Perf Week
5.19%
Perf Month
4.42%
Perf Quarter
40.40%
Perf Half Y
34.20%
Perf YTD
121.33%
Perf Year
112.49%
Perf 3Y
13.14%
Perf 5Y
-49.49%
Perf 10Y
-50.22%
Prev Close
21.42
Price
21.27
Change %
-0.70%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jellison William RFormer DirectorAug 07 '26Proposed Sale21.0716,864355,255Aug 07 05:28 PM
Fischetti Gary PDirectorAug 03 '26Buy20.751,00020,74553,015Aug 05 04:30 PM
Fischetti Gary PDirectorAug 04 '26Buy20.321,00020,31554,015Aug 05 04:30 PM
HENNEMAN JOHN B IIIDirectorMay 01 '26Buy14.665,00073,32054,871May 04 08:34 AM
Griffin Stephen D.President and CEOApr 30 '26Buy12.2912,200149,88136,163Apr 30 05:22 PM
Anika Therapeutics, Inc. engages in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.
Executive ChairDr. Cheryl Renee Blanchard Ph.D.
PresidentMr. Stephen D. Griffin
Senior VPMr. Ian W. McLeod
Executive Director of Corporate Development & Investor RelationsMr. Matthew Hall
VP & Chief Human Resources OfficerMs. Lisa Funiciello